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Abstract
Background: Disseminated dormant cancer cells can resume growth and eventually form overt metastases, but the
underlying molecular mechanism responsible for this change remains obscure. We previously established that cell surface
interaction between urokinase receptor (uPAR) and a5b1-integrin initiates a sequel of events, involving MAPK-ERK
activation that culminates in progressive cancer growth. We also identified the site on uPAR that binds a5b1-integrin.
Disruption of uPAR/integrin interaction blocks ERK activation and forces cancer cells into dormancy.
Methods and Principle Findings: Using a target structure guided computation docking we identified 68 compounds from a
diversity library of 13,000 small molecules that were predicted to interact with a previously identified integrin-binding site
on uPAR. Of these 68 chemical hits, ten inhibited ERK activation in a cellular assay and of those, 2 compounds, 2-(Pyridin-2-
ylamino)-quinolin-8-ol and, 2,29-(methylimino)di (8-quinolinol) inhibited ERK activation by disrupting the uPAR/integrins
interaction. These two compounds, when applied in vivo, inhibited ERK activity and tumor growth and blocked metastases
of a model head and neck carcinoma.
Conclusions/Significance: We showed that interaction between two large proteins (uPAR and a5b1-integrin) can be
disrupted by a small molecule leading to profound downstream effects. Because this interaction occurs in cells with high
uPAR expression, a property almost exclusive to cancer cells, we expect a new therapy based on these lead compounds to
be cancer cell specific and minimally toxic. This treatment, rather than killing disseminated metastatic cells, should induce a
protracted state of dormancy and prevent overt metastases.
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Introduction
There is long standing clinical evidence, some inferential, but
recently at the molecular level, that disseminated cancer cells can
persist in a patient in a dormant state with no symptoms before
they become actively growing to form overt metastases [1].
However, the mechanisms responsible for the conversion from
dormant to active state remain largely unknown. Our long term
goal is to identify molecular events that control cancer dormancy
and to find ways to mimic them with aim of inducing and
maintaining dormancy.
Previously, using a model of head and neck cancer, we
determined that a high ratio of MAPK-ERK to SAPK-p38
activity was necessary for these cells to form a progressively
growing tumor [2]. This ratio was subsequently found to be
predictive of the ability to form tumors by cells from multiple
cancers [1]. In the head and neck model this ratio was achieved
through the interaction of a5b1-integrin with urokinase receptor
(uPAR) which is highly expressed on these cells [3]. We showed
that this interaction activated the integrins [2] and that through an
‘‘outside in’’ activation process, EGFR was recruited to the
complex and activated signaling to ERK [4]. We also showed that
antibody directed to Domain III region of uPAR, a protein made
of 3 folded domains, but not other anti-uPAR antibodies,
disrupted the uPAR/integrin interaction.
Before initiating a search for small molecules capable of
disrupting uPAR/integrins association, we first identified the site
on uPAR to which the integrin bound; this site is located at
residues 240–248 of Domain III of uPAR [5]. The solved crystal
structure shows that the 3 folded domains of uPAR form a
urokinase binding pocket in the front of the molecule [6] while
residues 240–248 are located in the back of the structure.
Treatment of tumorigenic cells that possess a functional uPAR-
integrins complex with a peptide derived from uPAR residues
240–248 disrupted the complex, inactivated the a5b1-integrin,
and reduced signal to ERK, while the same peptide with S245A
substitution was inactive. The fact that a single amino acid was
responsible for the functionality of the complex increased the
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interaction.
Although, an antibody and a peptide are able to disrupt the
interaction, we believe that a small molecule with the same activity
would be preferable. Since disruption of uPAR/integrin interac-
tion shifts cells into proliferative arrest, without causing their
death, to be an effective treatment the drug would have to be used
chronically in patients suspected to have overt disseminated or
residual disease. For that reason it would have to have limited
toxicity and, 0preferably, be orally available. Because the library
was selected on the basis of Lipinski’s rule of 5 [7], and because of
the target which is an interaction that takes place when uPAR is
over-expressed, a condition mostly of malignant tumors, those two
requirement should be satisfied.
Our experimental model assigns an important role to a highly
expressed uPAR in regulating cancer dormancy [2,3,8]. It fits well
with the observations that high uPAR expression predicts for more
aggressive disease in several cancer types [9–14] and that
circulating and bone marrow cancer cells express uPAR [15–
17]. Simultaneous uPAR and HER2/neu gene amplification on
circulating cancer cells has also been described [14]. In gastric
cancer uPAR expression on cancer cells in bone marrow is a
prospective predictor of proliferation of these cells and shorter
patient survival [18]. These considerations prompted our search
for small molecules that might target the uPAR/integrin
interaction. We conducted computational screening of a diversity
library of ,13,000 small molecules using the uPAR crystal
structure [6] with a focus on the residues 240–248 region, which
we showed to be important for integrin interaction. This screen
identified 68 compounds, which were further characterized for
their effect on ERK inhibition using a tester cell line in which
luciferase expression was under the control of activated ERK.
Here we report evidence that 2-(Pyridin-2-ylamino)-quinolin-8-ol
and its analog, 2,29-(methylimino)di (8-quinolinol) were able to
functionally disrupt uPAR/integrin interaction. As a consequence
of the uPAR/integrin disruption, reflected in reduced ERK
activity, a significant inhibition of tumor growth was observed with
almost complete inhibition of metastases.
Results
In silico screening of a diversity library of small molecules
on uPAR
The in silico screening of a library of chemical compounds for
their potential to disrupt uPAR/integrins interaction is the
culmination of a long effort to find ways to induce cancer cell
dormancy. It was made possible by our identification of an
integrin binding sequence on uPAR [5] and the recently published
crystal structure of uPAR [6].
A diversity library of about 13,000 small molecules was screened
using Autodock (v 3.05) for possible binders to uPAR and to the
specific site on uPAR that binds integrin a5b1. The input
describing the protein was prepared with the program Autodock
Tools (ADT); it involved adding charges and non-bonded
parameters to the protein structure file and orienting the protein
to minimize the enclosing rectangle using an in-house program,
Simulaid. The screening and the filtering of the docked poses were
driven, respectively, by a script and a program (Dockres). Of the
top-scoring molecules that docked on uPAR (68 in total) 32
showed preferential docking on the sequence consisting of residues
240–248 (Fig. 1A) and those were further tested in a cell-based
assay.
We used a head and neck cancer (HNSCC) cell line, T-HEp3,
which expresses high level of uPAR and a5b1-integrin, which by
interacting are responsible for generating in vivo ERK activation
and proliferative signal [2]. We stably transfected the cells with 2
plasmids; pFA (ElkAD-GAL4DBD), which encodes for a fusion
protein that transactivates, when phosphorylated by ERK, a
second plasmid, pD700 (5X-GAL4UAS-tk-luciferase). These cells
were incubated for 16 hrs with 5 mM of the selected compounds,
lysed and tested for Luciferase activity. Luciferase activity
inhibition as percent of untreated control (Fig. 1B), and thus
ERK inhibition, by two of the compounds, MS#479 and
MS#128 was found to be similar to the inhibition of ERK by a
MEK inhibitor, PD98059, but the former two compounds were at
least 10 fold more effective than PD98059 (Fig. 1B). (At 5 mM
PD98059 was ineffective, Fig. 1B). From a search of the ZINC
database that contains over 4.6 million small molecules, we found
10 and 4 commercially available analogs for MS#479 and
MS#128, respectively, which were tested using the same
Luciferase activity assay as in Fig. 1B. Compared to the control,
the 3 analogs of the MS#479 compound inhibited Luciferase by
at least 30%, but less than the original compound which inhibited
by at least 60%, while one of the MS#128 analogs, MS#126,
inhibited Luciferase, and thus ERK-activity by 82% and slightly
more than the original compound (75%) (Fig. 1C).
To confirm that the observed drop in Luciferase activity was
indeed due to a reduction in ERK activity, we treated T-HEp3
monolayer cells with 20 mM of several of the active compounds for
45 min, lysed the cells and determined P-ERK and ERK content
by Western blotting. As shown in Fig. 1D, short incubation with
the compounds led to a profound inhibition of P-ERK content, in
some cases similar to the effect of an established MEK inhibitor,
PD98059.
Treatment of 2 melanoma cell lines, UCT-2 and A2058, both of
which express a5b1-integrin and have highly activated ERK
induced by mutated B-RAF, but no uPAR expression (Estrada, Y.
Dong, J-L. and Ossowski, L., Pigment Cell Melanoma Research,
In Press), with 20 mMo fM S #479 for 1 hr, did not cause
reduction in P-ERK by Western blot analysis while PD treatment
inhibited P-ERK (Results not shown), further confirming the
specificity of the uPAR/integrin as a target.
Mechanism of ERK inhibition by compounds
As stated earlier, uPAR/integrin interaction leads to ERK
activation, a process responsible for in vivo proliferation of T-HEp3
cells [2,3]. Disruption of this interaction, a tumor cell specific
target, causes a5b1-integrin inactivation and forces cancer cells
into a state of dormancy [2,8]. One important indication of a5b1-
integrin activation is its ability to bind fibronectin (FN) and to
organize it into insoluble fibrils on the cell surface [2,5,8]. To
identify among ERK inhibitors those that function through
inactivation of a5b-integrin, we tested the effect of the ‘‘docked’’
compounds (Fig. 1A) that inhibited ERK (Fig. 1C), as well as their
non-inhibitory analogs (Fig.S1), for their ability to interfere with
FN-fibril formation. T-HEp3 cell bound insoluble FN-fibrils were
detected by immunofluorescence (IF). After 16 hrs of incubation at
37uC we found that approximately 60% of cells in control cultures
had fibrils on their surface (Fig. 2A). The anti-uPAR antibody, R2,
which we previously showed to block fibril formation [8], was
again inhibitory. Of the 6 ERK inhibiting compounds tested, only
2, MS#479 and MS#305 showed a dose-dependent ability to
block fibrils, and at 10 mM were nearly as efficient as the anti-
uPAR antibody. The rest of the compounds, including 4
additional ERK inhibitors, (Fig. 2B) did not block fibril formation
(Fig. 2A and 2B), suggesting that they inhibit ERK through a
different mechanism. The two compounds, MS#479 and
MS#305 had a slight growth inhibitory effect on T-HEp3 cell
Small Molecules and Metastasis
PLoS ONE | www.plosone.org 2 February 2009 | Volume 4 | Issue 2 | e4617in culture when tested at 10 mM for longer than 40 hrs and at
7.5 mM for longer than 72 hrs.
To test directly the effect of compounds MS#479 and MS#305
on a5b1-integrin inactivation, T-HEp3 cells were incubated with
or without 1 mM MnCl2, or with 5 and 50 mM of the two active
compounds; MS#304, which inhibits ERK but does not disrupt
fibrils, served as negative control. Cells were then incubated with
HUTS-4 antibody that recognizes the active conformation of b1
integrin [19], or with an isotype matched IgG, followed by
secondary rabbit-anti mouse IgG antibody coupled to Alexa 488
and examined by FACS. As expected, (Fig. 2C), MnCl2 treatment
stimulated HUTS-4 binding by ,40% over control, while the 2
lead compounds inhibited HUTS-4 binding by ,15%; MS#304
had no effect. Several other ERK inhibiting compounds that did
not cause FN-fibril disruption were found to be ineffective in
integrin inactivation as determined by HUTS-4 antibody binding
(Results not shown).
We next tested whether the two compounds, by inactivating the
integrin will interfere with cell adhesion and spreading. Reduction
of adhesion might be important in depriving cells in vivo of a pro-
proliferative/survival signal and in reducing their ability to
migrate. Suspensions of T-HEp3 cells (1.5610
4) were treated for
10 min with increasing concentrations of the two lead compounds
and with an inactive compound MS#410 and inoculated into FN-
coated wells. (We used MS#410 because it does not disrupt
uPAR/integrin and does not inhibit ERK). Cells treated with anti-
uPAR antibody served as a positive control. Cells that attached
and spread after 15 min of incubation at 37uC were quantified.
The two lead compounds reduced cell adhesion to FN significantly
(p,0.01), and in a dose dependent fashion, while the inactive
compound tested at the highest concentration (20 mM) had no
effect (Fig. 2D).
Disruption of physical interaction of uPAR/integrin
complex by MS#479
To test the ability of compounds to physically disrupt the
uPAR/integrin complex, T-HEp3 cells were surface-biotinylated,
lysed and the complex immunoprecipiated by anti-uPAR domain
I antibody (R3) or by anti-a5b1 integrin antibody in the presence
of 0, 2.5 or 5 mM of compound MS#479, or an inactive
compound MS#410. Because the R3 antibody does not efficiently
immunoprecipitates uPAR, to show uPAR association with a5b1-
integrin using R3 required very long film exposures (Results not
shown). The proteins, resolved on PAGE, were probed with
Neutravidin after transfer; the integrin bands were also probed
Figure 1. In silico docking of small molecule library and analysis of top compounds. A. Docking of small molecule library onto uPAR.
In-silico screen of a diversity library selected on the basis of the Lipinski rule using Autodock (v 3.0.5) for possible binders to uPAR, targeting the
region comprising residues 240–248. B. Test of top-scoring compounds for ERK inhibition. T-HEp3 cells stably transfected with a plasmid
expressing Elk1-GAL4 fusion protein and plasmid expressing GAL4UAS-TATA-luciferase (pD700-luciferase), plated in 96 wells plates were treated
overnight with 5 mM of the top-scoring compounds generated by in silico docking of library of compounds on uPAR
240–248 sequence. The cells were
lysed and Luciferase activity was measured in triplicates. The numbers (mean of 3 determinations) show luciferase as % of diluents (DMSO) treated
control. *- PD98059, 5 mM, N250 mM. C. Structure activity relationship analysis of compounds MS#479 and MS#128. Promising ligands
(MS#479 and MS#128) were entered into the ZINC database of over 4.6610
6 small molecules, and commercially available analogs were selected for
further testing. The testing was as described for 1B. Each bar is the mean of 3 determinations. The experiment was repeated twice. D. Compounds
that inhibit luciferase activity also inhibit P-ERK. T-HEp3 cells transfected as in B, were treated with 20 mM of compound MS#479, 305, 304
and 128 for 20 min, lysed and tested for P-ERK by Western blotting. PD98059 (10 mM) served as a positive control.
doi:10.1371/journal.pone.0004617.g001
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integrin ratio are expressed as percent of untreated control.
Treatment with 2.5 mM of compound MS#479 reduced the
uPAR/integrin association by more than 70%, and 5 mM blocked
it altogether. This effect was more potent than the previously
shown disruption of uPAR/integrin association by 50 mMo f
uPAR-derived peptide residue 240–248 [5]. (Peptide 240–248
with alanine in place of serine 245 was completely inactive [5]). An
Figure 2. Testing ERK-inhibiting compounds for their effect on uPAR/integrin interaction. A. Inhibition of FN-fibril formation. T-
HEp3 cells in suspension were incubated with compounds MS#479, MS#305, MS#304 or MS#128 (10 mM) in DMEM with 5% FN-free FBS for
15 mins, inoculated into chambered slides and incubated overnight with DMEM with 10 mg/ml human FN. The cell-bound FN fibrils were detected by
IF as described in Methods. This experiment was repeated 3 times. B. Structure of compounds tested for Luciferase and FN-fibril inhibition.
Luciferase was examined as in Fig. 1B and fibril disruption as in Fig. 2A. C. Inactivation of b1-integrin. Monolayers of T-Hep3 cells were incubated
with 1 mM MnCl2, or 5 or 50 mM of compound MS#304, MS#305, or MS#479, cells were detached and incubated with 5 mg/ml antibody to active
b1-subunit of integrin (HUTS-4), or IgG2b, followed by anti-mouse IgG coupled with Alexa 488 and analyzed by FACS. The bars show mean
fluorescence intensity as percent of untreated control. This experiment was repeated twice with similar results. D. Inhibition of adhesion to FN. T-
HEp3 cells were treated in suspension with anti-uPAR domain III (R2) antibody (15 mg/ml), or with 5, 10 and 20 mM of compound MS#479 or MS#305
or with 20 mM compound MS#410 as negative control and adhesion was determined after 15 min at 37uC as previously described [5]. The results are
mean (SD) of 4 determinations. The results are statistically significant (ANOVA p,0.0001). This experiment was repeated twice with similar results.
doi:10.1371/journal.pone.0004617.g002
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the complex. Another active compound, MS#305 produced
similar results to MS#479, but at 5 and 10 mM, respectively
(Results not shown).
Compounds MS#479 and MS#305 inhibit tumor growth
We previously showed that uPAR with serine 245 to alanine
mutation was neither able to interact with the integrin nor to
stimulate in vivo proliferations [5]. We tested whether compounds
that docked to this sequence and showed potent in vitro disrupting
activity will affect the in vivo growth. T-HEp3 cells stably
transfected with plasmids ElkAD-GAL4DBD and the 5X-GA-
L4UAS-luciferase were pre-incubated for 20 min with 10 mM
MS#479, or the diluents alone, and inoculated on the
chorioallantoic membranes (CAMs) at 4610
5 cells/CAM,
treated daily with the compound for 5 consecutive days, excised,
weighed, lysed and the lysates used for Luciferase measurements.
As shown in Fig. 3B, left panel, MS#479 treatment inhibited
tumor weight by ,60% (p=0.0001, t-test), and Luciferase
activity, expressed as units per mg of tumor protein, by ,85%
(p=0.003 t-test)(Fig. 3B, right panel). Because Luciferase
expression in this cells is under control of uPAR/integrin
activated ERK, these results show that MS#479, by inhibiting
ERK, inhibits tumor growth.
Figure 3. Lead compounds inhibit tumor growth and metastasis through uPAR/integrin disruption and ERK inhibition. A.
Disruption of physical interaction between uPAR and a5b1-integrin. Confluent T-HEp3 cells were surface biotinylated, lysed and incubated
with Domain I anti-uPAR antibodies R3 (Cntr1), anti-a5b1-integrin antibody (HA5), or with isotype matched IgG, (Cntr 3). After 1 hr the precipitates
were treated for 15 min with 2.5 or 5.0 mM of compound MS#479 or MS#410 and the proteins analyzed by Western blotting using Neutravidin-HRP
conjugate for detection. Bottom panel; top portion of the upper blot was re-probed, after stripping, with anti-a5 integrin antibody. a5-integrin and
uPAR were scanned and quantified using Image J and the ratio of uPAR to integrin was determined. The bars represent the ratio expressed as percent
of control. This experiment was performed 3 times. B. In vivo treatment of T-HEp3 cells with compound MS#479 inhibits ERK activity and
tumor growth. T-HEp3 cells stably transfected with ELK-luciferase (as in Fig. 1C) were mixed with 10 mM of compound MS#479 in DMSO or DMSO
(0.1%) and inoculated on CAMs of 10 day old chick embryos at 4610
5 cells/CAM, 4 CAMs per group. The tumors were treated daily with 30 mlo f
10 mMM S #479 or 30 ml of 0.1% DMSO for 6 days, at which time the tumors were excised, weighed, lysed and Luciferase activity was determined as
described in Methods. The inhibition by compound #479 was statistically significant (n=7/group, tumor weight, p,0.0001, Luciferase, p,0.0001, t-
test). C. The effect of MS#479, MS#305 and MS#410 (negative control) on tumor growth and ERK inhibition measured by ELK-GFP
expression. T-HEP3 cells stably transfected with ELK-GFP construct were treated with the 3 compounds or DMSO as in B but 5610
5 were inoculated
and, at the end of the incubation, single cell suspensions of tumors were prepared and total as well as GFP-expressing cell number was determined
for each tumor. The graph shows the total number of tumor cells per tumor (mean, n=5, white bars) and percent of GFP-positive cells (darkened part
of bars). Both compounds significantly (ANOVA p,0.0001) inhibit tumor growth. MS#410 has no effect. D. The effect of compounds on
spontaneous metastasis. To quantify metastases, lungs were removed from chick embryos in experiment described in Fig. 3C, DNA was extracted
and used to amplify a 220 bp fragment of human alu sequence as previously described [21]. One of the MS#410 treated embryos was dead and 1
showed toxic effects.
doi:10.1371/journal.pone.0004617.g003
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metastasis?
To study the effect of uPAR/integrin disrupting compounds on
spontaneous metastasis we used stably transfected T-HEp3 cells,
similar to the one described above but in which the 5X-
GAL4UAS promoter was linked to hrGFP. We have shown
previously that T-HEp3 cells disseminate rapidly and predictably
to multiple organs when inoculated on the CAM [20] and that
PCR amplification of human alu sequences in DNA extracted
from chick embryo organs, including lungs, is an accurate measure
of the number of disseminated cancer cells [21]. We thus mixed
the T-HEp3 cells with 10 mMo fM S #479, MS#305 and, as
negative control, MS#410, inoculated the cells into Teflon rings
placed on CAMs and continued the daily treatments for additional
5 days. This treatment did not interfere with cell attachment to the
CAM, possibly because the CAM, in addition to FN, the ligand for
a5b1-integrin contains multiple other extracellular membrane
proteins, such as collagen and vitronectin that might mediated
HEp3 cell attachment. The percent of GFP positive cells was
determined in single cell suspensions of tumors using an inverted
fluorescent microscope. Fig. 3C, shows that both MS#479 and
MS#305produced strong (.60%) and significant (p,0.0001,
ANOVA) inhibition of tumor growth. In both cases, ELK-GFP
tracer cells, in which the GFP is proportional to the level of ERK
activation, reliably tracked the effect on overall tumor growth
(Fig. 3C, blackened part of the bars).
To test for the effect of compounds on metastases, DNA was
extracted from chick embryo lungs and their content of
disseminated cancer cells was measured by human alu-PCR
amplification as described previously [21]. Fig. 3D shows that
treatment with MS#479, results in a potent reduction in lung-
human alu sequences, indicating the presence of fewer dissemi-
nated cancer cells. MS#305 has somewhat lesser effect and the
inactive MS#410 is not inhibitory. This experimental approach
does not permit to conclude whether the effect on metastasis is due
to reduction in primary tumor size, an effect on dissemination due
to reduced migration or inhibition of cancer cells proliferation in
the secondary sites.
We have previously shown that in the case of uPAR/integrin
interaction, serine 245 was crucial for this interaction [5]. Indeed
we found that serine 245 of a small a-helix provides a crucial site
of molecular interaction (see Fig. 4A). It is located in a surface
exposed cavity that is lined with amino acid residues carrying
various functional groups capable of hydrogen bonding, electro-
static and hydrophobic interactions. Of these Pro 218, Asn 220,
Ser 245, Gln 248, Ala 244 interact with the lead compound. Polar
atoms of the protein located within 3A ˚ of the ligand (Fig. 4B)
suggest possible derivatives for improvement of ligand affinity.
Once such derivatives of medicinal quality are available, we will
examine the mechanism of dormancy induction in disseminated
cells.
Discussion
The main goal of this study was to identify small molecules that
by disrupting interaction between two receptors and inverting the
ratio between active ERK and p38 will force disseminated cancer
cells into a state of dormancy. This was based on our previous
work that delineated a positive loop leading from uPAR/integrin
interaction through ERK activation to transcriptional up-regula-
tion of uPAR and determined that interruption of this loop forces
cancer cells into dormancy [2–5,8]. We now identified two small
molecules with uPAR/integrin disrupting activity that reduce
ERK activation and, when applied to cancer cells in vivo, inhibit
growth.
Why is this approach preferable to direct blocking of ERK
activity by MEK inhibitors, or to blocking of integrin activation by
antagonists? The first and most important advantage is the relative
specificity of the target; an interaction that takes place in high
uPAR-expressing cells, such as cancer cells. The intended use of
these compounds is to prevent occurrence of overt metastases in
patients that harbor clinically undetectable residual disease. Since
the drug is expected to induce and maintain dormancy, rather
than cause acute cancer cell death, a successful outcome implies
prolonged treatments and thus the need for oral availability and
high index of specificity for cancer cells. We pose that inhibiting
ERK by disrupting uPAR/integrin interaction should be less toxic
than direct blocking of ERK activity through MEK inhibitors or
inactivation of integrins, both of which would have more broader
targets.
We and others have repeatedly shown that uPAR directly
interacts with integrins affecting their activation state and
changing intracellular signaling [3,14,22–26]. This has been
shown by FRET, co-immunoprecipitation (IP) and genetic
modifications of uPAR or the integrin. Only in specific instances
involving vitronectin as matrix, the role of uPAR on integrin
function was shown to be indirect [27]. Since uPAR does not
directly bind to FN, the preponderance of published data,
including our own, allows the conclusion that MS#479 disrupts
the existing interface between uPAR and the integrin and stops the
signaling cascade. This has been confirmed by multiple approach-
es, including FN-fibril disruption, reduced adhesion to FN, and
loss of ‘‘activation’’ epitopes on integrins (Fig. 2), which all point to
‘‘de-activation’’ of the integrin. Cells that express a5b1-integrin
but not uPAR, such as melanoma, were insensitive to the effect of
MS#479. We did not examine the effect of the two lead
compounds on disruption of other uPAR/integrin pairs. However,
our previous work has shown [5] that a3b1-integrin binds much
less efficiently to the identified 240–248 amino acid residue
sequence. Because other uPAR/integrin complexes might also be
important in generating proliferative signals in cancer cells, it
might be necessary to find specific molecules that will disrupt these
interactions.
Is it feasible that a 3-domain folded uPAR protein can
physically contact a5b1-integrin through a sequence in domain
III, which most likely is membrane proximal? In spite of extensive
effort by several outstanding laboratories, some controversies
regarding integrin conformation capable of ligand binding and the
mechanism of their activation still persist [28]. Although, it is
believed that integrin is in extended form when binding ligands,
there is also evidence based on electron microscope analysis
indicating that the extodomain of integrin bound to a fragment of
fibronectin (F7–F10) appears to be in a similar compact (bent)
conformation as the unbound extodomain [29]. This suggests that
ligands such as uPAR, smaller than the full length large matrix
proteins, can bind to the bent conformation. Whether this is
sufficient to fully activate integrin or whether additional interac-
tions need to take place, remains to be determined.
In our search for active compounds we combined biological
and biochemical approaches to identify the site of interaction
between the two receptors. We found the sequence 240–248,
(GCATASMCQ) to be the site of interaction, with serine 245
being a crucial residue. This information facilitated the in silico
screening of a library of compounds in that the computational
evaluation of chemical compound binding to the target protein
could be analyzed in greater detail. To the best of our knowledge
the disruption by a small molecule of extracellular domains of
Small Molecules and Metastasis
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signaling and biological outcomes has not been described,
adding to the novelty of our approach. It was previously thought
that due to the large surfaces area involved in protein/protein
interface [30], small molecules would not be optimal candidates
for disruption of these interactions. However, more recently, it
was concluded that a much smaller subset of the interface (‘‘hot-
spots’’) [31] for review, might be responsible for the high affinity
protein/protein interaction. It appears that in the case of uPAR/
integrin interaction, serine 245 of a small a-helix is located in a
surface exposed cavity that provides a crucial site for molecular
interaction (see Fig. 4A). Polar atoms of the protein located
within 3A ˚ of MS#479, (Fig. 4B) suggest possible derivatives for
improvement of its affinity. Since the lead compounds were
identified from a diversity library of compounds selected on the
basis of the Lipinski rule for drug-like properties, we expect that
it will be possible to further optimize our lead compounds by
chemical modifications.
In summary, we have found a potential cancer specific target,
uPAR/integrin interaction site, and used it to identify a small
molecule that, by disrupting this interaction, might be able to force
cancer cells into dormancy. This might provide opportunity to
convert residual disease in cancer patients into a chronic but
asymptomatic state.
Figure 4. Chemical structure of the lead compound and its interaction in the binding site in uPAR. A. Top-scoring pose of the ligand
MS#479 (magenta) shown in its binding pocket in uPAR. Side chains of polar residues within 3A ˚ of the ligand are highlighted; the rest of the protein
is displayed in a ribbon diagram. B. Hydrogen-bonding interactions. Polar atoms of the protein shown within 3A ˚ of the ligand suggest corresponding
derivatization for improvement of ligand binding affinity.
doi:10.1371/journal.pone.0004617.g004
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An ethics statement is not required for this work. Reagents and
Antibodies- BSA and human FN were purchased from Sigma
Chemical Co. (St.Louis, MO), Steady Glo lysis buffer from
Promega, (Madison, Wisconsin), Aprotonin and trypsin, from ICN
Biomedicals, Inc. (Aurora, OH), DMEM, glutamine, antibiotics
and Lipofectin from LifeTechnologies, Inc. (Grand Island, NY)
and FBS from JRH Biosciences (Lenexa, KS). Anti-P-ERK1/2
(anti-phospho-tyr-204, clone E4) was from Santa Cruz Biotech-
nology (Santa Cruz, CA), anti-ERK1/2 (clone MK12) from
Transduction Laboratories (Lexington, KY), anti-a5b1(HA5) and
rabbit anti-a5 antibodies from Chemicon International (Teme-
cula, CA), Alexa Fluor 488 F(ab9)2 fragment of rabbit anti-mouse
IgG (H+L) and Neutravidin HRP from Molecular Probes,
Invitrogen (Carlsbad, CA), monoclonal anti-uPAR domain III
(R2) and domain I (R3) antibodies were a gift from Dr. M. Ploug
(Finsen Institute, Copenhagen). COFAL-negative embryonated
eggs were from Specific Pathogen-Free Avian Supply (North
Franklin, CT); protein G-agarose beads were from Roche
Molecular Systems Inc., (Branchburg, NJ). FN-depleted serum
was prepared on a gelatin-Sepharose4B column as per manufac-
turer instruction. The compounds for testing were provided by the
Translational Chemical Biology Center (TCBC), Mount Sinai
School of Medicine.
Computer Screening of compounds
A diversity library of about 13,000 small molecules selected on
the basis of the Lipinski rule for drug-like properties [7] was
screened in-silico using Autodock (v 3.0.5) for possible binders to
uPAR, targeting the region comprising residues 240–248. The
input describing the protein was prepared with the program ADT
(Autodock Tools) that add charges and non-bonded parameters to
the protein structure file. The protein was further oriented to
minimize the enclosing rectangle using an in-house program
Simulaid (developed by M. Mezei). The screening was driven by a
script that runs the docking of several ligands on a cluster of CPUs
in parallel, allowing the full screening to be completed in a couple
of weeks. The docked poses were sorted and the top-scoring
molecules were tested experimentally by using biochemical and
cell-based assays as described above.
Test of top-scoring compounds for ERK inhibition using
ELK-luciferase or Western blot for phospho-ERK
T-HEp3 cells [32] were transiently co-transfected with pFA-
Elk1-fusion plasmid and pD700 -luciferase plasmid as previously
described [33]. These plasmids report through Luciferase activity
level, on the state of ERK- activation. After 24 hrs cells were
serum-starved for 5 hrs, and treated with 5 or 50 mM of PD98059
or 5 mM of the test compound dissolved in DMSO and diluted in
DMEM. Following 16 hr incubation, the cells were lysed directly
in Steady glo-luciferase lysis buffer (1:1) from Promega and
Luciferase activity measured using Tecan Safire2
TM and Magellan
6.0 software. To analyze the effect on P-ERK, T-HEp3 cells were
serum starved and treated with 20 mM PD98059 or compounds
for 20 min, lysed in RIPA buffer (1% Triton X-100, 0.1%SDS,
10 mM Tris pH 8.0, 140 mM NaCl and protease inhibitors) for
30 min on ice, centrifuged and the supernatants (20 mg protein)
were analyzed by Western blotting using anti-P-ERK and anti-
ERK antibodies.
Disruption of FN- fibrils
T-HEp3 cells were suspended in 5% FN-depleted FBS/
DMEM without or with 10 mM compound MS#479, MS#305,
MS#304, MS#128, or anti-uPAR antibody (R2, 20 mg/ml),
incubated for 15 min at room temperature, seeded in chambered
slides and incubated at 37uC. After 1 hr, medium with 10 mg/ml
of human FN was added and the cells were fixed and stained for
FN after additional 16 hrs of incubation. The images were
observed in fluorescent Nikon Eclipse E600 microscope and
photographed with SPOT-RT
TM camera, Spot Diagnostic
Instruments (Sterling Height, MI).
Inhibition of b1 integrin activity examined by FACS
analysis
T-HEp3 cells incubated with compound MS#304, MS#305
and MS#479 (5 and 50 mM) or MnCl2 (0.5 mM) for 20 mins,
were detached, resuspended in DMEM and aprotinin (20 mg/
ml) at 5610
5 cells/100 ml and incubated with antibody (5 mg/
ml) to active b1-conformation (HUTS-4) or isotype matched
(IgG2b) IgG at 37uC for additional 15 min in the presence of
compounds, followed by rabbit anti-mouse Alexa 488-coupled
IgG (1:400) at 4uC for 25 min, suspended in FACS buffer (1%
BSA in PBS with 10 mg aprotinin) and analyzed in FACS Canto
(Becton Dickinson, CA) using FACSDiva software. The numbers
show mean fluorescence intensity of HUTS-4 as percent of
untreated control.
Adhesion Assay
T-HEp3 cells were tested for adhesion as previously described
[5]. Briefly, cells were mixed with 15 mg/ml anti-uPAR antibody
(R2), (positive control) or the compounds MS#479, MS#305 at 5,
10 and 20 mM and compound MS#410 at 20 mM before
inoculation on wells pre-coated with 0.4 mg/ml of fibronectin.
Following 15 min incubation at 37uC, the cells were processed as
previously described [5]. The graph represents mean (6S.D.) of
four determinations for each sample.
Disruption of uPAR/a5b1-integrin complex
Surface biotinylated T-HEp3 cell lysates were prepared as
described [5] and 1 mg protein per sample was IP-ed with 5 mgo f
anti-a5b1(HA5), anti-uPAR (R3) antibodies, or isotype-matched
IgG bound to G-agarose beads. Compounds MS#479 and
MS#410 at 2.5 or 5 mM were added for the last 15 min of IP.
The bead-bound proteins were analyzed as previously described
[5]. The upper panel of the blot was stripped and re-probed with
rabbit anti-a5 antibody. The bands were scanned and quantified
using Image J and the uPAR associated with a5-integrin
represented as percent of the diluent treated control.
Effect of compounds on tumor growth and metastasis
T-HEp3 cells were stably transfected with plasmids reporting
for active ERK as described for Fig. 1B except that in some
experiments the reporter was GFP. Cells (4610
5 /30 ml) in PBS
with 0.05% DMSO, 10 mMo fM S #410 (control), or MS#479 or
MS#305 were inoculated into 8 mm Teflon rings placed on
CAMs of 10 day old chick embryos, 4 CAMs per group and
treated daily with 30 ml PBS/DMSO or PBS/compounds for 5
consecutive days. Tumors were weighed, and either minced and
lysed for Luciferase activity measurements or, when generated by
T-HEp3-ELK-GFP- cells, dissociated into single cell suspensions
and total tumor cells and GFP-expressing cells were counted using
Nikon TS100 fluorescent microscope. For the effect of compounds
on spontaneous metastasis, the embryo lungs from the above
experiment were dissected and the DNA was extracted and used to
amplify a 220 bp fragment of human alu sequence as we
previously described [21].
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Figure S1 Structure of compounds that docked on uPAR but
did not inhibit ERK nor disrupt fibrils. A library of compounds
was docked on uPAR (as described in Material and Methods) and
those that docked were examined for their ability to inhibit ERK
using ERK-luciferase HEp3 tester cells (see Material and
Methods), and for their ability to disrupt cell surface fibronectin
fibrils (as a measure of a5b1-integrin inactivation, see Material and
Methods for details). The structures of compounds without
inhibitory activities are depicted here. Compounds that inhibited
ERK were tested further.
Found at: doi:10.1371/journal.pone.0004617.s001 (0.09 MB TIF)
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